Elsevier

Pathology

Volume 45, Issue 7, December 2013, Pages 637-644
Pathology

The prognostic significance of the BRAFV600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry

https://doi.org/10.1097/PAT.0000000000000008Get rights and content

Summary

Aims

BRAFV600E mutation has been shown in a large metaanalysis to be an independent prognostic marker for papillary thyroid carcinoma (PTC) with poorer survival and higher recurrence rates.

Methods

We studied prevalence of BRAFV600E mutation in 77 patients with PTC from an Australian cohort using competitive polymerase chain reaction (C-PCR) and immuno- histochemistry (IHC) with BRAFV600E-specific antibody, VE1. Clinicopathological parameters, recurrence and mortality were analysed according to BRAFV600E mutation status.

Results

Median follow-up was 84.5 months. BRAFV600E mutation was demonstrated in 65% of cases combining both C-PCR and IHC; in 71% (37/77) of tumours >1cm and 52% (13/25) of microcarcinomas (<1 cm). IHC was positive in 69% (49/71) and C-PCR in 53% (41/77); 87% (67/77) of our patients were treated with total thyroidectomy and 65% (50/77) also had radioactive ablation. BRAFV600E positive tumours had a significantly higher rate of subsequent lymph node metastases (p — 0.035). Significant association was found between BRAFV600E mutation and male sex (p—0.034), but not between age >45 years at diagnosis, size of primary tumour, extrathyroidal extension, lymph node or distant metastases or clinical stage at diagnosis.

Conclusions

BRAFV600E mutation in PTC determined by IHC is associated with significantly increased risk of lymph node recurrence.

References (49)

  • V.A. LiVolsi

    Papillary thyroid carcinoma: an update

    Mod Pathol

    (2011)
  • M. Rivera et al.

    Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns

    Mod Pathol

    (2010)
  • P. Carbonell et al.

    Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E

    J Mol Diagn

    (2011)
  • R.A. Smith et al.

    Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant

    Hum Pathol

    (2011)
  • S.A. Hundahl et al.

    A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S. 1985-1995

    Cancer

    (1998)
  • K.C. Loh et al.

    Pathological tumor-nodemetastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients

    J ClinEndocrinolMetab

    (1997)
  • B.A. Kilfoy et al.

    International patterns and trends in thyroid cancer incidence, 1973-2002

    Cancer Causes Control

    (2009)
  • L. Davies et al.

    Increasing incidence of thyroid cancer in the United States, 1973-2002

    JAMA

    (2006)
  • M. Xing

    BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications

    Endocr Rev

    (2007)
  • M. Roring et al.

    Aberrant B-Raf signaling in human cancer - 10 years from bench to bedside

    Crit Rev Oncog

    (2012)
  • T.H. Kim et al.

    The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis

    Cancer

    (2012)
  • R.P. Tufano et al.

    BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis

    Medicine (Baltimore)

    (2012)
  • M. Xing

    Molecular pathogenesis and mechanisms of thyroid cancer

    Nat Rev Cancer

    (2013)
  • D. Capper et al.

    Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

    Acta Neuropathol

    (2011)
  • Cited by (33)

    • Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma

      2018, Pathology Research and Practice
      Citation Excerpt :

      Although the VE1 monoclonal antibody has been shown to be a highly sensitive and specific antibody for the immunohistochemical detection of BRAF V600E mutation in a variety of primary and metastatic tumors, a full and practical standard in clinical setting has not been done [19]. The sensitivities range from 89% to 100% and specificities range from 61.5% to 100% in PTC [14,15,19,25–32]. The optimal scoring criteria for this antibody in PTC specimens are not well defined.

    • Use of monoclonal antibodies to detect specific mutations in formalin-fixed, paraffin-embedded tissue sections

      2016, Human Pathology
      Citation Excerpt :

      Generally, VE1 immunostaining of a cytology specimen is less specific than that of a surgical specimen for detection of the BRAF V600E mutation [70,71]. BRAF mutation in PTC determined by IHC is associated with significantly increased risk of lymph node recurrence [72]. Succinate dehydrogenase (SDH) mutations in one of the SDH genes lead to succinate accumulation and very low fumarate levels.

    • Immunohistochemical detection of NRAS<sup>Q61R</sup> protein in follicular-patterned thyroid tumors

      2016, Human Pathology
      Citation Excerpt :

      Some mutation-specific antibodies are recently available for immunohistochemistry (IHC) performed on formalin-fixed, paraffin-embedded (FFPE) tissue sections. For example, the antibody VE1 for BRAFV600E is a useful and reliable tool for BRAFT1799A detection in thyroid lesions, especially in PTC [9–13]. There is also a newly developed mutation-specific antibody for NRASQ61R that appears to be a powerful detection tool for the mutation in malignant melanoma [14,15].

    • BRAF V600E mutation-specific antibody: A review

      2015, Seminars in Diagnostic Pathology
      Citation Excerpt :

      There is some indication that vemurafenib produces a clinical response in patients with BRAF V600E-mutant metastatic PTC and could even have efficacy in the setting of anaplastic thyroid carcinoma harboring a BRAF mutation.54,55 IHC with the VE1 antibody has demonstrated a high concordance rate with molecular methods with sensitivities ranging from 89% to 100% and specificities from 61.5% to 100% in FFPE tissue from PTC specimens (Table).21,39,46,56–64 An example of a PTC harboring a BRAF V600E mutation stained for BRAF V600E is shown in Fig. B.

    • Risk of malignancy for each Bethesda class in pediatric thyroid nodules

      2015, Journal of Pediatric Surgery
      Citation Excerpt :

      Therefore the adult guidelines for BV lesions are reasonable for children, and each case must be individually tailored depending on other risk factors, concomitant contralateral thyroid disease, patient wishes etc. For BIV nodules, the rate of papillary thyroid cancer was 50 per cent and frozen section, which may be able to definitively diagnose papillary carcinoma, may therefore have a much higher yield to confirm cancer than in adult BIV nodules, where less than 15 per cent will be papillary thyroid cancers [11–18]. The diagnostic dilemma of BIII nodules in adults seems to be equally challenging in pediatric patients with a malignancy risk of around 18 per cent.

    View all citing articles on Scopus

    these authors contributed equally

    View full text